Cerus SEC Filings

Cerus Corporation reported that it has released preliminary product revenue results for the fourth quarter and full year ended December 31, 2025, along with an outlook, through a press release referenced in this report. These figures are described as preliminary, unaudited and subject to completion of the company’s normal financial closing procedures, and the final results may differ from these early estimates, with any differences potentially being material.

The company notes that its independent registered public accounting firm has not audited or reviewed these preliminary numbers and does not provide any assurance on them. Cerus emphasizes that the product revenue information should not replace full financial statements prepared under U.S. GAAP and cautions against placing undue reliance on the preliminary data. The information in this report and the accompanying press release is being furnished, rather than filed, and is not automatically incorporated into other SEC filings.

Cerus Corporation (CERS)11/24/2025, the officer sold 55,000 shares of Cerus common stock in an open market transaction coded as "S" at a price of $1.70 per share. Following this sale, the officer beneficially owns 728,294 shares of Cerus common stock, held in direct ownership.

Cerus Corporation (CERS) filed its Q3 2025 10‑Q, showing higher sales and near breakeven results. Product revenue reached $52.7 million, up from $46.0 million a year ago, and government contract revenue was $7.5 million versus $4.6 million. Gross profit on product revenue was $28.1 million compared with $26.2 million. The quarter’s net loss attributable to Cerus was $19 thousand, or $0.00 per share.

Operating expenses rose with R&D at $15.8 million and SG&A at $18.6 million. For the nine months, product revenue was $148.4 million and government contract revenue was $20.8 million, with a net loss of $13.4 million. Cash and cash equivalents were $15.7 million and short‑term investments $62.8 million. Total debt was $84.9 million, with $36.2 million classified as current and $48.7 million as non‑current. Inventories increased to $68.1 million, including $53.1 million current. Net cash used in operating activities for the nine months was $1.4 million. As of October 17, 2025, common shares outstanding were 192,087,501. No shares were sold under the at‑the‑market program, leaving approximately $96.8 million available.

Cerus Corporation (CERS) reported its third-quarter 2025 results for the period ended September 30, 2025. The company furnished a press release titled “Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance” as Exhibit 99.1.

The information was furnished under Item 2.02 and is not deemed filed for liability purposes. An Inline XBRL cover page was included as Exhibit 104.

CERUS CORP reporting person Dean A. Gregory (Director) effected a purchase of 25,000 shares of Cerus common stock on 08/25/2025 at a price of $1.25 per share. After the transaction the reporting person beneficially owned 86,725 shares. The Form 4 was filed by one reporting person and executed by an attorney-in-fact, Chrystal N. Jensen.

Baker Bros. Advisors and related persons disclosed ownership stakes in Cerus Corporation (CERS) in Amendment No. 11 to a Schedule 13G/A. The filing reports that two Baker Brothers funds (667, L.P. and Baker Brothers Life Sciences, L.P.) beneficially own a combined 12,883,844 shares, representing 6.7% of Cerus based on 191,160,480 shares outstanding as of April 17, 2025. The cover pages show Julian C. Baker and Felix J. Baker each with beneficial ownership of 12,903,708 shares (6.8%), which reflects their direct holdings including 19,864 in-kind distributed shares. The filing states the Adviser has sole voting and dispositive power over the funds' shares. The amendment is signed and dated 08/14/2025.